JP2010523696A5 - - Google Patents

Download PDF

Info

Publication number
JP2010523696A5
JP2010523696A5 JP2010503205A JP2010503205A JP2010523696A5 JP 2010523696 A5 JP2010523696 A5 JP 2010523696A5 JP 2010503205 A JP2010503205 A JP 2010503205A JP 2010503205 A JP2010503205 A JP 2010503205A JP 2010523696 A5 JP2010523696 A5 JP 2010523696A5
Authority
JP
Japan
Prior art keywords
methyl
dose
effective amount
carboplatin
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010503205A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010523696A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/059905 external-priority patent/WO2008124822A1/en
Publication of JP2010523696A publication Critical patent/JP2010523696A/ja
Publication of JP2010523696A5 publication Critical patent/JP2010523696A5/ja
Pending legal-status Critical Current

Links

JP2010503205A 2007-04-10 2008-04-10 脳腫瘍を治療する方法 Pending JP2010523696A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91097507P 2007-04-10 2007-04-10
PCT/US2008/059905 WO2008124822A1 (en) 2007-04-10 2008-04-10 Method of treating brain cancer

Publications (2)

Publication Number Publication Date
JP2010523696A JP2010523696A (ja) 2010-07-15
JP2010523696A5 true JP2010523696A5 (enExample) 2011-07-14

Family

ID=39831435

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010503205A Pending JP2010523696A (ja) 2007-04-10 2008-04-10 脳腫瘍を治療する方法

Country Status (9)

Country Link
US (1) US20100129470A1 (enExample)
EP (1) EP2144504A4 (enExample)
JP (1) JP2010523696A (enExample)
KR (1) KR20100016385A (enExample)
CN (1) CN101742910A (enExample)
AU (1) AU2008236993A1 (enExample)
CA (1) CA2720982A1 (enExample)
NZ (1) NZ580866A (enExample)
WO (1) WO2008124822A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006138608A2 (en) * 2005-06-16 2006-12-28 Myriad Genetics, Inc. Pharmaceutical compositions and use thereof
EP2144887A4 (en) * 2007-04-10 2012-10-03 Myrexis Inc PHARMACEUTICAL FORMS AND METHOD FOR THE TREATMENT OF CANCER
CA2720989A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Methods for treating cancer
WO2008124828A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Methods for treating vascular disruption disorders
CA2720983A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Method of treating melanoma
AU2009268547A1 (en) * 2008-07-11 2010-01-14 Myrexis, Inc. Pharmaceutical compounds as cytotoxic agents and the use thereof
US20110224240A1 (en) * 2010-01-11 2011-09-15 Myrexis, Inc. Methods of treating cancer and related diseases
KR101343959B1 (ko) 2012-09-19 2013-12-24 한국기계연구원 통합 코팅 장치
KR102257647B1 (ko) * 2013-06-05 2021-05-31 싸이트알엑스 코포레이션 암 치료용 세포독성제
CN105288629B (zh) * 2014-05-28 2021-02-19 北京大学 具有药效叠加作用及毒性分散效应的组合药物
WO2016168637A2 (en) * 2015-04-17 2016-10-20 Duquesne University Of The Holy Spirit Cyclopenta[d]pyrimidines and substituted cyclopenta[d]pyrimidines as antitubulin and microtubule targeting agents, monocyclic pyrimidines as tubulin inhibitors, and pyrrolopyrimidines as targeted antifolates and tubulin and multiple receptor tyrosine kinase inhibition and antitumor agents
WO2019211829A1 (en) * 2018-05-02 2019-11-07 Tel Hashomer Medical Research Infrastructure And Services Ltd. Compositions and methods for treating glioblastoma
KR20250172902A (ko) * 2018-07-31 2025-12-09 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트 투여에 의한 전이성 뇌종양의 치료
CN116143693A (zh) * 2020-06-24 2023-05-23 中国药科大学 一种具有抗肿瘤活性的2-甲基喹啉类衍生物及其合成方法和用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999061428A1 (en) * 1998-05-28 1999-12-02 Parker Hughes Institute Quinazolines for treating brain tumor
US7001926B2 (en) * 2000-03-10 2006-02-21 Oxigene, Inc. Tubulin binding agents and corresponding prodrug constructs
US20040229960A1 (en) * 2001-07-13 2004-11-18 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
US7326685B2 (en) * 2001-09-21 2008-02-05 The Administrators Of The Tulane Educational Fund Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof
US7470723B2 (en) * 2003-03-05 2008-12-30 Celgene Corporation Diphenylethylene compounds and uses thereof
US7618975B2 (en) * 2003-07-03 2009-11-17 Myriad Pharmaceuticals, Inc. 4-arylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof
JP2007502807A (ja) * 2003-08-18 2007-02-15 ファイザー・プロダクツ・インク Ｅｒｂｂ２抗がん剤の投与スケジュール
GB0321648D0 (en) * 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
US8258145B2 (en) * 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
CA2592971A1 (en) * 2005-01-03 2006-07-13 Myriad Genetics Inc. Method of treating brain cancer
SI3248600T1 (sl) * 2005-02-18 2020-09-30 Abraxis Bioscience, Llc Kombinacije in načini dajanja terapevtskih sredstev in kombinacijska terapija
WO2006138608A2 (en) * 2005-06-16 2006-12-28 Myriad Genetics, Inc. Pharmaceutical compositions and use thereof
US20070249640A1 (en) * 2005-06-16 2007-10-25 Myriad Genetics, Incorporated Pharmaceutical compositions and use thereof
US20070065449A1 (en) * 2005-09-16 2007-03-22 Claire Verschraegen Method of treating cancer, especially soft tissue sarcoma utilizing gemcitabine in combination with docetaxel and anti-VEGF therapy (bevacizumab)
CA2720983A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Method of treating melanoma
WO2008124828A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Methods for treating vascular disruption disorders
CA2720989A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Methods for treating cancer
EP2144887A4 (en) * 2007-04-10 2012-10-03 Myrexis Inc PHARMACEUTICAL FORMS AND METHOD FOR THE TREATMENT OF CANCER
WO2009023876A1 (en) * 2007-08-16 2009-02-19 Myriad Genetics, Inc. Method of treating non-small cell lung cancer

Similar Documents

Publication Publication Date Title
JP2010523696A5 (enExample)
JP2013503174A5 (enExample)
Zhang et al. Smart Cu (II)-aptamer complexes based gold nanoplatform for tumor micro-environment triggered programmable intracellular prodrug release, photodynamic treatment and aggregation induced photothermal therapy of hepatocellular carcinoma
US11224599B2 (en) Therapeutic agents and methods
EP1951729A4 (en) OXYGEN-LINKED PYRIMIDINE DERIVATIVES
Zorzi et al. A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium
RU2018102078A (ru) Комбинированная терапия противоопухолевым алкалоидом
EA201890146A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
NZ593343A (en) Combination cancer treatment conprising Abraxane and an inflamatory inhibitor
JP2008535902A5 (enExample)
CR7693A (es) Terapia de combinacion para enfermedades hiperproliferativas
RU2012111235A (ru) Комбинированная терапия композициями наночастиц таксана и ингибиторами хэджхог
MX2007009649A (es) Derivados de meleimida, composiciones farmaceuticas y metodos para el tratamiento del cancer.
WO2005117954A3 (en) Compositions and methods for treatment of neovascular diseases
EP2481402A3 (en) Nanoparticle comprising rapamycin and albumin as anticancer agent
TW201107327A (en) Therapeutic combination comprising a PLK1 inhibitor and an antineoplastic agent
EP2004637A1 (en) Substituted ring fused azines and their use in cancer therapy
WO2009012096A3 (en) Improved therapeutic methods and compositions comprising chroman ring compounds
WO2009120697A4 (en) Method and compositions for treatment of cancer
PH12012500504A1 (en) N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine in the treatment of antimitotic agent resistent cancer
JP2015514756A5 (enExample)
JP2009506054A5 (enExample)
US11702443B2 (en) Therapeutic agents and methods
JP2013520499A5 (enExample)
HUP0301247A2 (hu) Antitumor terápia disztamicin származékokkal